Session » Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2911

A Comparison of Gastrointestinal Disease Severity in African American and Caucasian Scleroderma Patients

9:00AM-11:00AM: Abstract Number: 2895

Adaptation of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Questionnaire into Turkish

9:00AM-11:00AM: Abstract Number: 2915

An Increased Circulating Level of Periostin in Patients with Systemic Sclerosis: Associations with Functional Impairment in Various Affected Organs

9:00AM-11:00AM: Abstract Number: 2898

Anti-Reflux Medications in Diffuse Cutaneous Systemic Sclerosis: Is Empiric Use of Proton Pump Inhibitors Supported?

9:00AM-11:00AM: Abstract Number: 2908

Anti-Vinculin Antibodies: A Novel Biomarker in Systemic Sclerosis, and Its Association with Vascular Involvement

9:00AM-11:00AM: Abstract Number: 2914

Association of Radiographic Findings in Hand X-Ray with Autoantibodies in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2909

Attitudes Toward Patient-Reported Outcome Instruments for the Assessment of Raynaud’s Phenomenon in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2887

Clinical Predictors for Development of Interstitial Lung Disease in Mixed Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 2922

Disability, Fatigue, and Their Associates in Early Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2894

Efficacy of Rituximab in Systemic Sclerosis with Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2890

Feasibility of Same Day Adipose Tissue Harvest, Cell Processing and Subcutaneous Delivery of Adipose Derived Regenerative Cells into Fingers of Scleroderma Patients within a Randomized Double Blind Clinical Trial

9:00AM-11:00AM: Abstract Number: 2913

Four Year Effects of Combined Bosentan and Iloprost Treatment on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion and Clinical Status, in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2899

Impact of the Clinical Characteristics of Systemic Sclerosis in Patients Quality of Life

9:00AM-11:00AM: Abstract Number: 2897

Microvascular Function in Systemic Sclerosis Patients with End-Stage Vascular Manifestations of the Disease

9:00AM-11:00AM: Abstract Number: 2917

Nailfold Capillaroscopy and Mortality in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2921

Patient Participation in Patient Reported Outcome Instrument Development in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2912

Performance of the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Systemic Sclerosis -Associated Interstitial Lung Disease (SSc-ILD)

9:00AM-11:00AM: Abstract Number: 2905

Predictors of Poor Hand Function in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2902

Preliminary Evaluation of Gastroesophageal Reflex Disease Outcome Measures in Scleroderma– Scleroderma Clinical Trials Consortium Gastrointestinal Working Group

9:00AM-11:00AM: Abstract Number: 2919

Prevalence of Antiphospholipid Antibodies and Their Clinical Associations in Systemic Sclerosis: Data from a French Cohort

9:00AM-11:00AM: Abstract Number: 2891

Prognostic Significance of Autoantibody Positivity in Interstitial Lung Disease: A Retrospective Case-Control Study

9:00AM-11:00AM: Abstract Number: 2904

Rituximab in Systemic Sclerosis-Interstitial Lung Disease, a Case Series of 18 Patients

9:00AM-11:00AM: Abstract Number: 2896

Safety and Effectiveness of Hyperbaric Oxygen Therapy for Systemic Sclerosis Ulcers

9:00AM-11:00AM: Abstract Number: 2907

Serum KL-6 Levels in Interstitial Lung Diseases (ILDs) Associated to Connective Tissue Diseases (CTDs)

9:00AM-11:00AM: Abstract Number: 2892

Serum Level of KL-6, a Biomarker of Interstitial Lung Disease (ILD), Is Higher in Diffuse SSc Than in Limited SSc and RA Even When the Activity of ILD Is Low

9:00AM-11:00AM: Abstract Number: 2901

SSc and the Significance of Blood Group Antigens

9:00AM-11:00AM: Abstract Number: 2918

The Clinical Relevance of Common ANA Patterns in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2920

The Effect of Rituximab on B Cells in Skin and Peripheral Blood in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2900

The Incidence and Prevalence of Systemic Sclerosis in Northwestern Part of Turkey

9:00AM-11:00AM: Abstract Number: 2916

The Number of Micro-Haemorrhages and Micro-Thrombosis Detected By Nailfold Videocapillaroscopy Is a Good Predictor of Disease Activity in Systemic Sclerosis: The Validation Study of NEMO Score

9:00AM-11:00AM: Abstract Number: 2906

The Survival and Prognostic Factors of Patients with Systemic Sclerosis Turkish Experience

9:00AM-11:00AM: Abstract Number: 2889

Therapeutic Plasma Exchange for the Treatment of Raynaud’s and Digital Ulcers in Systemic Sclerosis: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2903

Transition of Nailfold Microangiopathy throughout Different Patterns of Microvascular Damage and Correlations with Organ Involvement in Systemic Sclerosis: A Twelve Year Follow-up

9:00AM-11:00AM: Abstract Number: 2888

Usefulness of Bosentan in the Prevention of Pulmonary Hypertension in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2893

Usefulness of the Eustar Preliminary Criteria for Vey Early Systemic Sclerosis and Le Roy Criteria for Early-Systemic Sclerosis in Identifying Patients at Risk of Development of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2910

Work Productivity in Systemic Sclerosis and Association with Health Related Quality of Life

« View all sessions from this meeting